MedTrace Logo

Prognostic Factors of COVID19

NCT04405726 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-06-25

No results posted yet for this study

Summary

COVID-19 is an emerging disease, for which no specific treatment options are currently available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event (religious meeting), the Strasbourg University Hospital (HUS) had faced a sudden increase of the number of COVID-19-positive patients in serious condition requiring hospitalization. At the same time, many people develop only mild or moderate symptoms. To date, the prognostic factors for the course of SARS-CoV-2 infection are unknown. The primary purpose of the "COVID-HUS" protocol is to investigate viral and host-related factors to understand the pathophysiology of COVID infection and to open the way for new diagnostic, prognostic and therapeutic strategies against SARS CoV-2 .

The secondary objectives are

* Monitoring of viral replication of SARS-CoV-2 in the blood and respiratory tract in infected patients
* Monitoring of the humoral and cellular response directed against SARS-CoV-2
* Identification of factors leading to significant and / or prolonged viral replication of SARS-CoV-2 in the blood or respiratory samples
* Evaluation of the benefit of possible treatments implemented following the diagnosis of SARS-CoV-2 infection
* Exploration of the B and T immune repertoire sequences targeting SARS-CoV-2 in infected patients
* Typing of the HLA system in infected patients

Conditions

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Samira FAFI-KREMER, PharmD, PhD · Laboratoire de Virologie Plateau Technique de Microbiologie

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-27
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405726 on ClinicalTrials.gov